SLC5A2 and type 2 diabetes mellitus: Although they are still in their infancy as a treatment option for type 2 diabetes, SGLT2 inhibitors have quickly become one of the most popular options owing to their ability to reduce cardiovascular risks associated with the disease and their success in controlling blood glucose levels.